

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07D 209/34, A61K 31/40, C07K 5/062	A1	(11) International Publication Number: WO 96/32380 (43) International Publication Date: 17 October 1996 (17.10.96)
(21) International Application Number: PCT/EP96/01165 (22) International Filing Date: 14 March 1996 (14.03.96) (30) Priority Data: 9507298.9 7 April 1995 (07.04.95) GB (71) Applicant (for all designated States except US): PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): BATTISTINI, Carlo [IT/IT]; Via G. Verga, 1, I-20026 Novate Milanese (IT). BALLINARI, Dario [IT/IT]; Via C. Jannozzi, 8, I-20097 S. Donato Milanese (IT). ERMOLI, Antonella [IT/IT]; Via Garibaldi, 13, I-20090 Buccinasco (IT). PENCO, Sergio [IT/IT]; Via P. Marchesi, 24/9, I-20153 Milan (IT). VIOGLIO, Sergio [IT/IT]; Via delle Genziane, 10, I-20095 Cusano Milanino (IT).	(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	

(54) Title: SUBSTITUTED INDOLYLMETHYLENE-OXINDOLE ANALOGUES AS TYROSINE KINASE INHIBITORS

(57) Abstract

Indol-3-ylmethylene-2-oxindole derivatives having general formula (I), wherein one or two of R, R₁, R₂ and R₃ are a substituent selected independently from:

a) a -X-(CH₂)_m-NH₂, -X-(CH₂)_m-NR₄R₅, or -X-(CH₂)_m-NHR₆ group, b) a -NHC(NH)NH₂, -NHC(NH)NR₄R₅, -NHC(NH)NHR₆, -N=CH-NH₂, -N=CH-NR₄R₅ or -N=CH-NHR₆ group, c) a -X-(CH₂)_m-COR₇ group, d) a -COR₈ or COR₉ group, e) a -Y-CO-Y'-R₉ group, f) a -NHR₆ or -NHR₁₀ group, and the pharmaceutically acceptable salts of salt forming compounds of formula (I), have tyrosine kinase inhibiting activity.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SUBSTITUTED INDOLYLMETHYLENE-OXINDOLE ANALOGUES AS
TYROSINE KINASE INHIBITORS

The present invention relates to new derivatives of
5 substituted indolylmethylene-oxindoles, to a process for
their preparation, to pharmaceutical compositions
containing them and to their use as therapeutic agents,
in particular in treating a patient in need of tyrosine
kinase inhibition.

10 International applications WO91/13055 and WO93/01182
disclose indolylmethylene-oxindole derivatives endowed
with high in-vitro tyrosine kinase inhibiting activity.
However, such methylen-oxindole derivatives, similarly to
other known tyrosine kinase inhibitors, are characterized
15 by high lipophylicity, low aqueous solubility and
consequently low bioavailability.


However, the task to combine in the same molecule a high
tyrosine kinase inhibiting activity and adequate
hydrosolubility cannot be achieved by merely introducing
20 hydrophilic groups into the structure of in-vitro active
tyrosine kinase inhibitors, as this strategy results in
most cases in a significant loss of inhibitory activity.
Indeed, as known in the art, the therapeutic efficacy of
all drugs is strongly influenced by different parameters
25 that can affect their bioavailability. Object of the
present invention is therefore to provide novel
indolylmethylene-oxindole compounds endowed with improved

-2-

bioavailability.

Accordingly, the present invention provides novel indol-3-ylmethylene-2-oxindole derivatives having the following general formula (I)

5



(I)

wherein

one or two of R, R₁, R₂ and R₃ are a substituent selected independently from:

- a) a $-X-(CH_2)_m-NH_2$, $-X-(CH_2)_m-NR_4R_5$, or $-X-(CH_2)_m-NHR_6$ group, in which X is $-O-$, $-S-$ or $-NH-$, m is an integer of 1 to 4, one of R₄ and R₅ is hydrogen or C₁-C₆ alkyl and the other is C₁-C₆ alkyl or R₄ and R₅ taken together with the nitrogen atom to which they are linked form a C₄-C₇ saturated heteromonocyclic ring, and R₆ is C₂-C₆ alkanoyl or the terminal carbonyl group of a peptidyl residue containing from 1 to 3 aminoacids wherein the terminal amino group is either free or in a protected form or in an alkylated form to provide a $-NR_4R_5$ group in which R₄ and R₅ are as defined above;
- b) a $-NHC(NH)NH_2$, $-NHC(NH)NR_4R_5$, $-NHC(NH)NHR_6$, $-N=CH-NH_2$, $-N=CH-NR_4R_5$ or $-N=CH-NHR_6$ group in which R₄, R₅ and R₆ are as defined above;
- c) a $-X-(CH_2)_m-COR_7$ group wherein X and m are as defined

-3-

above, R_7 is hydroxy, amino, C_1 - C_6 alkoxy or $-NR_4R_5$ in which R_4 and R_5 are as defined above, or R_7 is the terminal amino group of a peptidyl residue containing from 1 to 3 aminoacids;

- 5 d) a $-COR_6$ or COR_6 group in which R_6 is the terminal amino group of a peptidyl residue containing from 1 to 3 aminoacids and R_8 is C_1 - C_4 alkoxy unsubstituted or substituted by phenyl or R_8 is a $-(CH_2)_n-NH_2$, $-(CH_2)_n-NR_4R_5$ or $-(CH_2)_n-NHR_6$ group in which n is 1 or
10 2 and R_4 , R_5 and R_6 are as defined above;
- e) a $-Y-CO-Y'-R_9$ group wherein each of Y and Y' which may be the same or different is $-NH-$ or $-O-$ and R_9 is phenyl or C_1 - C_6 alkyl unsubstituted or substituted by phenyl; and
- 15 f) a $-NHR_6$ or $-NHR_{10}$ group in which R_6 is as defined above and R_{10} is C_1 - C_6 alkyl substituted by 1 to 3 hydroxy groups;

and the others R , R_1 , R_2 and R_3 are independently chosen from hydrogen, halogen, amino, hydroxy, C_1 - C_6 alkyl, C_1 - C_6
20 alkoxy, carboxy, C_1 - C_6 alkoxy-carbonyl, C_2 - C_6 alkanoyloxy, cyano and $-NR_4R_5$ in which R_4 and R_5 are as defined above, and the pharmaceutically acceptable salts of salt forming compounds of formula (I).

The invention includes within its scope all the possible
25 isomers, stereoisomers, in particular Z- and E-isomers and their mixtures, and the metabolites and the metabolic precursors or bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).

-4-

A $-(CH_2)_n-$ group may be a branched or straight C_1-C_4 alkylene chain, typically $-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-$ and $(CH_3)_2CH-\overset{|}{CH}-$, in particular $-CH_2-$ and $-CH(CH_3)-$.

- 5 The alkyl groups, and the alkyl moiety in the alkanoyl groups, may be branched or straight alkyl chain. A C_1-C_6 alkyl group is preferably a C_1-C_4 alkyl group, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl, in particular methyl or ethyl.
- 10 A C_1-C_6 alkoxy group is, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy or tert.butoxy, preferably methoxy, ethoxy or propoxy.

- When R_4 and R_5 taken together with the nitrogen atom to which they are linked form a C_4-C_7 saturated hetero-
- 15 monocyclic ring, said ring can optionally contain a further heteroatom chosen from nitrogen, oxygen and sulphur. Typically said ring is a pyrrolidine, piperidine or morpholino ring.

- Examples of aminoacids forming a peptidyl residue
- 20 according to the meaning of R_4 , R_5 and R_7 given above are alanine, glycine, histidine, threonine, glutamic acid, aspartic acid and tyrosine; preferably glycine, alanine and glutamic acid.

- Accordingly, the R_6 terminal carbonyl group and the
- 25 relevant peptidyl residue together may form a peptidoyl radical selected, for instance, from the group including $-CO-CH(CH_3)-NH_2$, $-CO-CH(CH_3)-NHCO-CH(CH_3)-NH_2$, $-CO-CH(NH_2)-CH(OH)CH_3$ and $-CO-CH(CH_3)-NHCO-CH(NH_2)-CH_2-CH_2-COOH$, in

-5-

which the terminal amino group may be either free or in a protected or alkylated form as stated above.

Similarly the R_6 or R_7 terminal amino group and the relevant peptidyl residue is, for instance, a group
5 selected independently from $-\text{NH}-\text{CH}(\text{CH}_3)-\text{COOH}$, $-\text{NH}-\text{CH}_2-\text{COOH}$, $-\text{NH}-\text{CH}(\text{COOH})\text{CH}(\text{OH})\text{CH}_3$, $-\text{NH}-\text{CH}(\text{CH}_3)\text{CONH}-\text{CH}(\text{CH}_3)\text{COOH}$, $-\text{NH}-\text{CH}(\text{COOH})\text{CH}_2-\text{CH}_2-\text{COOH}$, $-\text{NH}-\text{CH}(\text{COOH})\text{CH}_2\text{COOH}$ and $-\text{NH}-\text{CH}(\text{COOH})\text{CH}_2\text{-phenyl}$.

When R_6 is the terminal carbonyl group of a peptidyl
10 residue as defined above in which the terminal amino group is in a protected form, said amino group may be protected in a conventional way as known from the chemistry of peptides. Typically by an amino protecting group chosen from benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, t.butoxycarbonyl (Boc), biphenylylisopropoxy-
15 carbonyl (BBoc), 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), 0-nitrobenzenesulfonyl (Nps), trimethylsilylethoxycarbonyl, di-p-nitrophenylethoxycarbonyl and trichloroethoxycarbonyl (Troc).

20 Preferably said amino protecting group being chosen from butoxycarbonyl (Boc) and 9-fluorenylmethyloxycarbonyl (Fmoc).

When R_8 is C_1-C_4 alkoxy substituted by phenyl it is in particular benzyloxy or phenethyloxy.

25 A $-(\text{CH}_2)_n-$ group may be, for instance, a $-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)-$ group, preferably $-\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)-$.

When R_9 is C_1-C_6 alkyl substituted by phenyl it is preferably a phenyl- C_1-C_4 alkyl group, in particular

-6-

benzyl or phenethyl.

A C₁-C₆ alkyl group substituted by 1 to 3 hydroxy groups is preferably C₁-C₄ alkyl substituted by 1 or 2 hydroxy groups, typically HOCH₂-CH(OH)-CH₂- or HOCH₂-CH₂-CH₂-.

5 A halogen atom is, for instance, fluorine, chlorine, bromine or iodine, preferably a fluorine, chlorine or bromine atom.

A C₂-C₆ alkanoyl group, or alkanoyl moiety in alkanoyloxy groups, is preferably a C₂-C₄ alkanoyl group, in particular acetyl, propionyl or butyryl.

Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts, with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids, or organic, e.g. acetic, 15 propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids, and salts with inorganic, e.g. alkali metal, especially sodium or potassium, bases or alkaline-earth metal, especially calcium or magnesium bases, or 20 with organic bases, e.g. alkylamines, preferably triethyl-amine.

As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the 25 compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which nevertheless upon administration to a human being are converted directly or indirectly in vivo into a compound

-7-

of formula (I).

Preferred compounds of the invention are the compounds of formula (I) in which

one of R , R_1 , R_2 and R_3 is independently a substituent
5 selected from

a') $-X-(CH_2)_m-NH_2$, $-X-(CH_2)_m-NR_4R_5$ or $-X-(CH_2)_m-NHR_6$ in which
 X is oxygen or $-NH-$, m is 1 or 2, one of R_4 and R_5 is
 C_1-C_4 alkyl and the other is hydrogen or C_1-C_4 alkyl or
 R_4 and R_5 taken together with the nitrogen atom to
10 which they are linked form a pyrrolidine or
piperidine ring, and R_6 is C_2-C_4 alkanoyl or the
terminal carbonyl group of a peptidyl residue
containing 1 or 2 aminoacids;

b') $-NHC(NH)NH_2$ or $-N=CH-NR_4R_5$ in which one of R_4 and R_5 is
15 C_1-C_4 alkyl and the other is hydrogen or C_1-C_4 alkyl;

c') $-X-(CH_2)_m-COR_7$ in which X is $-O-$ or $-NH-$, m is 1 or 2,
 R_7 is hydroxy, C_1-C_4 alkoxy, amino or R_7 is the
terminal amino group of a peptidyl residue containing
1 or 2 aminoacids;

20 d') a $-COR_8$ or $-COR_9$ group in which R_8 is as defined above
and R_9 is C_1-C_4 alkoxy unsubstituted or substituted
by phenyl or R_9 is $-(CH_2)_n-NH_2$ or $-(CH_2)_n-NR_4R_5$ in
which n is 1 or 2 and one of R_4 and R_5 is C_1-C_4 alkyl
and the other is hydrogen or C_1-C_4 alkyl or R_4 and R_5
25 taken together with the nitrogen atom to which they
are linked form a pyrrolidine or piperidine ring; and

e') $-NHR_6$ or $-NHR_{10}$ in which R_6 is C_2-C_4 alkanoyl or the
terminal carbonyl group of a peptidyl residue

-8-

containing 1 or 2 aminoacids and R_{10} is C_1-C_4 alkyl substituted by one or two hydroxy groups; and the others are independently chosen from hydrogen, halogen, amino, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_2-C_4 alkoxy carbonyl, C_2-C_4 alkanoyloxy, cyano C_1-C_4 alkylamino or di(C_1-C_4 alkyl)-amino; and the pharmaceutically acceptable salts of salt forming compounds of formula (I).

Examples of specific compounds of the invention are the following compounds which, when appropriate, may be either Z- or E-diastereoisomers or Z,E-mixtures of said diastereoisomers:

5-aminomethylcarbonyl-3-(indol-3-yl-methylene)-2-indolinone;

3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone (internal code FCE 28484);

5-(2,3-dihydroxy-propylamino)-3-(5-methoxy-indol-3-ylmethylene)-2-indolinone (internal code FCE 28524);

3-(5-dimethylaminomethyleneamino-indol-2-ylmethylene)-2-indolinone (internal code FCE 28732);

N-[3-(5-bromo-2-indolinone-3-ylidenemethyl)-indol-5-yl]guanidine (internal code FCE 28885);

6-L-alanylamino-[3-(5-methoxy-indol-3-ylmethylene)-2-indolinone] (internal code FCE 28934);

5-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone (internal code FCE 28901);

5-L-glutamyl-L-alanylamino-3-[(5'-methoxy-3'-indolyl)

-9-


methylene]-2-indolinone (internal code FCE 28437);
and the pharmaceutically acceptable salts of salt forming
members of the group.

The compounds of the invention, and the pharmaceutically
5 acceptable salts thereof, can be obtained, for instance,
by a process comprising:

a) reacting an aldehyde of formula (II)




wherein R and R₁ are as defined above, with a
10 compound of formula (III)



wherein R₂ and R₃ are as defined above; or




-10-

b) reacting a compound of formula (IV)




wherein

one or two of R' , R'_1 , R'_2 and R'_3 are $-OH$, $-NH_2$ or $-SH$
 5 and the others are as R , R_1 , R_2 and R_3 as defined
 above, with an alkylating agent of formula (V)
 selected from



in which Z is a halogen atom and m , R_4 , R_5 , R_6 and R_7
 are as defined above, thus obtaining a compound of
 formula (I) wherein one or two of R , R_1 , R_2 and R_3 are
 15 as defined above under a) or c); or



c) reacting a compound of formula (VI)



-11-

wherein

one or two of R'' , R''_1 , R''_2 and R''_3 are $-OH$ or $-NH_2$ and the others are as R , R_1 , R_2 and R_3 as defined above, with an acylating agent of formula (VII) selected from



or a reactive carbonyl derivative thereof, wherein R_2 , R_8 , Y' and R_9 are as defined above, thus obtaining a compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are as defined above under d) or e); and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof, and/or, if desired, converting a salt into a free compound, and/or, if desired, separating a mixture of isomers of a compound of formula (I) into the single isomers.

The reaction of a compound of formula (II) with a compound of formula (III) is an analogy process which can be carried out according to known methods, as herebelow described; preferably in the presence of a basic catalyst, e.g. pyridine, piperidine, dimethylamine, or a suitable alkali metal hydroxide or alkoxide.

For example the reaction of a compound of formula (II) with a compound of formula (III) may be carried out under the conditions of the Knoevenagel reactions as described,

-12-

e.g., by G. Jones in Organic Reactions 15, 204 (1967). Suitable catalysts are organic bases such as pyridine, piperidine or diethylamine.

The condensation may be performed in an inert organic solvent, e.g. pyridine, ethanol, methanol, benzene or dioxane at temperatures ranging from about 0°C to about 100°C.

Preferably the reaction is carried out in warm ethanol solution in the presence of piperidine catalyst.

10 In a compound of formula (V) the halogen atom Z is, for instance, iodine or bromine or chlorine, preferably bromine.

Alkylation of a compound of formula (IV) can be carried out according to known methods, for instance by reaction with sodium hydride and the bromide of a compound of formula (V) in a high boiling aromatic solvent such as xylene.

A reactive derivative of a carboxylic acid of formula (VII) is, for instance, a halide, e.g. an acyl chloride or an anhydride, typically a mixed anhydride or an in situ generated activated form from the carboxylic acid and a coupling reagent such as benzotriazole-1-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate (PyBOP).

20 Acylation reaction of a compound of formula (VI) with a compound of formula (VII) is preferably carried out in the presence of a basic agent such as pyridine, at a temperature ranging from about 0°C to about 50°C.

A compound of formula (I) can be converted into another

-13-

compound of formula (I) according to known methods. For instance, a compound of formula (I) in which one or two of R , R_1 , R_2 and R_3 are carboxy and the others are as defined above can be converted into a corresponding
5 compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are a group $-\text{COR}_4$ in which R_4 is as defined above, by acylation reaction with a suitable aminoacid or peptide in an organic solvent, e.g. CH_2Cl_2 , in the presence of a basic agent such as pyridine or N-methyl-
10 morpholine.

A compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are an amino group and the others are as defined above can be converted into another compound of formula (I) in which one or two of R , R_1 , R_2 and R_3 are a group
15 $-\text{NHR}_{10}$ in which R_{10} is as defined above, by a two-steps process. Accordingly, for instance, an amino group is reacted with 3-formyl-2,2-dimethyl-1,3-dioxolane followed by treatment with a reducing agent such as NaBH_3CN , thus converting the amino group into a 2,3-isopropylidene-
20 dioxypopylamino group, which in its turn is treated with trifluoroacetic acid to obtain a $-\text{NHR}_{10}$ group wherein R_{10} is 2,3-dihydroxypropyl.

A compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are amino and the others are as defined above can
25 be converted into another compound of formula (I) in which one or two of R , R_1 , R_2 and R_3 are $-\text{NHC}(\text{NH})\text{NH}_2$, for instance by reaction with di(tert.butoxycarbonyl)thiourea ($+0-\text{CONHCSNHCOO}+$) according to known methods. The

-14-

guanidino substituted compound thus obtained can in its turn be converted into another compound of formula (I) in which one or two of R , R_1 , R_2 and R_3 are a group $-NHC(NH)NR_4R_5$ or $-NHC(NH)CR_6$ in which one or two of R_4 and R_5 are C_1-C_6 alkyl and R_6 is as defined above according to well known alkylation or acylation methods, respectively. Similarly a compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are amino and the others are as defined above can be converted, according to known methods, into another compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are a $-N=CHNR_4R_5$ group.

For instance, an amino substituted compound can be reacted with a suitable di(C_1-C_6 alkyl)N-CHO aldehyde in a suitable polar solvent, e.g. a lower alkanol, typically methanol or ethanol, in the presence of a basic agent, such as piperidine, to obtain a $-N=CHNR_4R_5$ compound in which R_4 and R_5 are C_1-C_6 alkyl.

The optional salification of a compound of formula (I) as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional methods.

For example, the separation of a mixture of geometric isomers, e.g. cis- and trans-isomers, may be carried out by fractional crystallization from a suitable solvent or by chromatography, either column chromatography or high pressure liquid chromatography.

The intermediate compounds of formula (II) and (III) can

-15-

be obtained according to known methods from known compounds, for instance as described in WO 91/13055 and WO 93/01182. The people skilled in the art will appreciate that the intermediate compounds of formulae
5 (II) and (III) can be submitted to the same substituent chemical modifications as described in connection with the compounds of formula (I).

However, these substituent modifications can be properly performed at different levels within the process on the
10 base of convenience depending on the nature of the substituents and on the compatibility of the transformations with the involved chemical structures. The intermediate compounds of formula (IV), (V), (VI) and (VII) are known compounds or can be obtained from known
15 compounds. For instance, most of the compounds of formula (IV) and (VI) are known from WO 91/13055 and WO 93/01182 or can be similarly obtained.

Compounds of formula (III) (oxindole derivative), if not available, can also be obtained from the corresponding
20 indole derivative by an analogy process through known methods. A preferred one is an oxidation-reduction process comprising the use of pyridinium bromide perbromide using a tertiary alcohol as solvent, preferably ter.butanol, followed by a reductive treatment
25 with zinc in acetic acid or hydrogenation in the presence at palladium on charcoal.

When in the new compounds of the present invention and in the intermediate products used for their preparation

-16-

there are groups present which need to be protected before the above-described reactions are performed, they may be protected before the reaction takes place and then deprotected at the end of the reaction according to well known methods in organic chemistry.

PHARMACOLOGY

The compounds of the invention possess specific tyrosine kinase inhibiting activity. It is believed that tyrosine kinase inhibitors may be of great importance in the control of uncontrolled cellular reproduction, i.e. in cellular reproduction disorders.

Recent studies on the molecular basis of neoplastic transformation have identified a family of genes, designated oncogenes, whose aberrant expression causes tumorigenesis. For example, the RNA tumour viruses possess such an oncogene sequence whose expression determines neoplastic conversion of infected cells. Several of their oncogene-encoded proteins, such as pp60^{v-src}, p70^{src-yes}, p130^{src-fps} and P70^{src-fgr} display protein tyrosine kinase activity, that is they catalyze the transfer of the γ -phosphate from adenosine triphosphate (ATP) to tyrosine residues in protein substrate. In normal cells, several growth factor receptors, for example the receptors for PDGF, EGF, α -TGF and insulin, display tyrosine kinase activity.

Binding of the growth factor (GF) activates the receptors tyrosine kinase to undergo autophosphorylation and to

-17-

phosphorylate closely adjacent molecules on tyrosine. Therefore, it is thought that the phosphorylation of these tyrosine kinase receptors plays an important role in signal transduction and that the principal function of tyrosine kinase activity in normal cells is to regulate cell growth. Perturbation of this activity by oncogenic tyrosine kinases that are either overproduced and/or display altered substrate specificity may cause loss of growth control and/or neoplastic transformation.

Accordingly, a specific inhibitor of tyrosine kinase can be useful in investigating the mechanism of cancerogenesis, cell proliferation and differentiations and it can be effective in prevention and chemotherapy of cancer and other pathological proliferative conditions.

Hence the compounds according to the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans.

A human or animal, e.g. a mammal, can thus be treated by a method comprising the administration thereto of a therapeutically effective amount of one of the compounds of the invention. In this way the condition of the human or animal may be improved. Amelioration of the disease state or disorder from which the human or animal is suffering can be achieved. Typical examples of such disorders are benign and malignant tumors, including leukaemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour, malignant neoplasm of the bladder, breast, lung or thyroid, neoplasias of

-18-

epithelial origin, such as mammacarcinoma. Moreover, they can be useful in the treatment of epidermal hyperproliferation, such as psoriasis. The compounds of the invention can also be useful in inhibiting the development of the atheromatous plaque and restenosis, in the control of angiogenesis, as anti-metastatic agents and in treating diabetic complications. They have also utility as immunomodulating agents in the control of immune system diseases, e.g. as immunosuppressants, and in the treatment of Alzheimer's disease, as far as protein tyrosine kinases are involved in these diseases.

The tyrosine specific protein kinase activity of the compounds of the invention is shown, e.g., by the fact that they are active in the in vitro and in vivo test described herebelow.

In-vitro Assay

p45 v-abl Kinase Purification

The enzyme used in our test was the p45 v-abl tyrosine kinase which represents the catalytic domain of the Abelson tyrosine kinase (isolated from the Abelson murine leukaemia virus). The p45 v-abl kinase was produced and isolated as described by Wang et al. in J. Biol. Chem. 260, 64 (1985) and by Ferguson et al. in J. Biol. Chem. 260, 3652 (1985) and in Biochem. J. 257, 321 (1989).

p45 v-abl Kinase Assay

(Val⁵)-Angiotension II phosphorylation was performed by

-19-

incubation with 40 ng of purified abl-kinase and (γ - 32 P)-ATP, in 50 μ l of buffer containing Tris-HCl 25 mM, pH 8.0, MgCl₂ 10 mM and dithiothreitol 0.1 mM (kinase buffer). The reaction mixture was incubated for the indicated time at 30°C and the reaction stopped by adding 50 μ l of 5 % trichloroacetic acid. After a brief incubation on ice, tubes were centrifuged. The supernatants were spotted on phosphocellulose paper squares (Whatman P-81) and washed extensively in acetic acid. The radioactivity bound to dried phosphocellulose squares was measured in a liquid scintillation counter. IC₅₀ values were calculated from triplicated determinations of each experimental point. Each inhibitor was tested at concentrations ranging from 0 to 400 μ g in the presence of fixed concentrations of peptide (2 Mm) and ATP (50 μ M).

In-vivo Assay

K562 Cell Growth Inhibition Assay

K562 cells, a human myelogenous leukemia cell line, were seeded into a 24 wells tissue culture plate (Falcon 3047) (10000/well) in the presence of increasing concentrations of the compounds. After 72 h, cells were harvested and were counted using a cell counter (Coulter Counter - ZM). The percent of inhibition was evaluated in respect to the untreated control cells.

The inhibitory activity data for a representative group of compounds according to the present invention, obtained

-20-

both in the in-vitro p45 v-abl kinase assay and in the in-vivo human chronic myeloid leukemia K562 cell growth inhibition assay described above, are set out in following Table 1.

5 Table 1. Inhibition of p45 kinase and K562 cell growth

Compound	IC ₅₀ (μM)	
	<u>v-abl</u>	<u>K562</u>
FCE 28484	0.78	4.82
10 FCE 28437	0.5	14.75

where

FCE 28484 means 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone; and

15 FCE 28437 means 5-L-glutamyl-L-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone.

In view of their high activity, the compounds of the invention can be used in medicine in treating a patient in need of tyrosine kinase inhibition.

20 The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by
25 intravenous injection of infusion; or topically. The dosage depends on the age, weight, condition of the patient and administration route. For example, the dosage adopted for oral administration to adult humans for the compound FCE 28484 may range from about 10 to about 150-
30 200 mg per dose, from 1 to 5 times daily. Of course,

-21-

these dosage regimens may be adjusted to provide the optimal therapeutic response.

The invention includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, lauryl-sulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example by means of mixing, granulating, tableting, sugar-coating or film-coating processes.

-22-

The liquid dispersion for oral administration may be, e.g., syrups, emulsions and suspensions.

The syrup may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or
5 sorbitol.

The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.

10 The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine
15 hydrochloride.

The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous, isotonic saline solutions.

20 The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

Compositions for topical application, e.g. creams,
25 lotions or pastes, can be prepared by admixing the active ingredient with a conventional oleaginous or emulsifying excipient.

A further object of the present invention is a combined

-23-

method of treatment of cancer or of amelioration of the conditions of mammals, including humans, suffering from cancer, said method comprising administering

- 1) a compound of the invention, or a pharmaceutically acceptable salt thereof,
5 and
- 2) an additional antitumor agent, in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

10 The present invention also provides products containing a compound of the invention, or a pharmaceutically acceptable salt thereof, and an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

15 The term "antitumor agent" is meant to comprise both a single antitumor drug and "cocktails" i.e. a mixture of such drugs, according to the clinical practice.

Examples of antitumor agents that can be formulated with a compound of the invention or, alternatively, can be
20 administered in a combined method of treatment, include doxorubicin, daunomycin, epirubicin, idarubicin, 4'-iododoxorubicin, methoxy-morphlino-doxorubicin, etoposide, fluorouracil, melphalan, cyclophosphamide, bleomycin, vinblastin and mitomycin or a mixture of two
25 or more thereof.

The compounds of the invention can therefore be used in a treatment to ameliorate a cancer. They may be

-24-

administered to a patient suffering from a cancer treatable with an antitumor agent, for example an anthracycline glycoside such as doxorubicin, daunomycin, epirubicin or idarubicin as mentioned above, together
5 with the antitumor agent.

A compound of the invention and an antitumor agent such as an anthracycline glycoside can be administered to improve the condition of a patient having a leukaemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuro-
10 blastoma, Wilm's tumour or malignant neoplasm of the bladder, breast, lung or thyroid.

The following examples illustrate but do not limit the invention.

Example 1

15 Preparation of FCE 28484

To a suspension of aluminum chloride anhydrous (11.4 g, 85 mmole) in 1,2-dichloroethane (10 ml) was added dropwise bromoacetyl bromide (5.9 ml, 68 mmole) with stirring at 0°C.

20 After the stirring was continued 1 h, 2-indolinone (4.52 g, 34 mmole) dissolved in 1,2-dichloroethane (10 ml) was added, the mixture was stirred 2 h at 0°C and then heated 3 h at 50°C.

The reaction mixture was poured into ice and water (500
25 ml) and filtered to give 5-(2-bromoacetyl)-2-indolinone (7.5 g).

A solution of piperidine (0.39 ml, 3.9 mmole) and 5-(2-

-25-

bromoacetyl)-2-indolinone (500 mg, 1.97 mmole) in N,N-dimethylformamide (15 ml) was stirred at room temperature 4 h then was poured into water (50 ml) and washed with dichloromethane (250 ml), the organic solution was washed
5 with water several times and dried over sodium sulfate. After evaporation of the solvent the residue was chromatographed on silica-gel using ethyl acetate as eluant to give 5-(2-piperidin-1-yl-acetyl)-2-indolinone (250 mg).

10 To a solution of indole-3-carboxaldehyde (150 mg, 1.03 mmole) and 5-(2-piperidin-1-yl-acetyl)-2-indolinone (250 mg, 0.97 mmole) in ethanol (10 ml) piperidine (0.15 ml, 1.5 mmole) was added with stirring at 80°C. After the stirring was continued 3 h the mixture gave a
15 solid that was filtered and washed with ethanol to give 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone (FCE 28484) (250 mg).

¹H NMR (400 MHz, DMSO, δ ppm)

1.3-1.6 (m, 6H); 2.50 (m, 4H); 3.78 (s, 2H); 6.93 (d, J=7.9 Hz, 1H); 7.25 (m, 2H); 7.53 (m, 1H); 7.86 (dd, J=1.7 Hz, J=8.2 Hz, 1H); 8.22 (m, 1H); 8.29 (s, 1H); 8.50 (d, J=1.7 Hz, 1H); 9.45 (s, 1H); 10.8 (bs, 1H); 12.0 (bs, 1H).

FD-MS: m/z 386 (39 [MH]⁺); 385 (33 [M]⁺); 98 (100 [C₆H₁₂]⁺)

-26-

By proceeding analogously, with proper modification introducing the amino group by using the Gabriel synthesis, the following compound can be obtained:

5-aminomethylcarbonyl-3-(indol-3-yl-methylene)-2-indolinone.

Example 2

Preparation of FCE 28524

To a solution of 5-methoxy-indole-3-carbaldehyde (175 mg, 1 mmole) and 5-terbutoxycarbonylamino-2-indolinone (250 mg, 1 mmole) in ethanol (20 ml) piperidine (0.1 ml, 1 mmole) was added with stirring at 80°C.

After the stirring was continued 8 h the mixture gave a solid that was filtered and washed with ethanol to give 3-(5-methoxy-indol-3-yl-methylene)-5-terbutoxycarbonyl-amino-2-indolinone (255 mg).

The solid was taken up with dichloromethane (10 ml) and trifluoroacetic acid (2 ml) was added with stirring at room temperature.

After 1 h dichloromethane (50 ml) was added and the mixture was washed with water and made alkaline with 2 N sodium hydroxide and then washed several times with water and dried over sodium sulfate and concentrated under reduced pressure, the solution after standing overnight at 4°C gave crystals that were filtered and washed with cold dichloromethane to obtain 3-(5-methoxy-indol-3-yl-methylene)-5-amino-2-indolinone (200 mg).

-27-

To a solution of 3-(5-methoxy-indol-3-yl-methylene)-5-amino-2-indolinone (200 mg, 0.65 mmole), 2,2-dimethyl-[1,3]dioxolane-4-carbaldehyde (170 mg, 1.3 mmole) and 1 N hydrochloric acid (1 ml) in methanol (10 ml) sodium
5 cyanoborohydride (220 mg, 3.25 mmole) was added with stirring at room temperature.

After the stirring was continued 4 h, the reaction mixture was diluted with dichloromethane (100 ml) and washed several times with water.

10 The organic layer was dried over sodium sulfate and concentrated under reduced pressure, the residue was chromatographed on silica-gel using a mixture of ethyl acetate and methanol (9:1) as eluant to give 5-[(2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-amino]-3-(5-methoxy-
15 indol-3-ylmethylene)-2-indolinone (120 mg).

To a solution of 5-[(2,2-dimethyl-[1,3]dioxolan-4-yl-methyl)-amino]-(5-methoxy-indol-3-ylmethylene)-2-indolinone (120 mg, 0.28 mmole) in dichloromethane (15 ml) trifluoroacetic acid (1 ml) was added with stirring
20 at 0°C.

After the stirring was continued 1 h the solution was diluted with dichloromethane (100 ml) and washed with saturated sodium bicarbonate and then with water.

The organic layer was dried over sodium sulfate and
25 concentrated under reduced pressure, the residue was chromatographed on silica-gel using a mixture of ethyl acetate and methanol (9:1) as eluant to give 5-

-28-

(2,3-dihydroxy-propylamino)-3-(5-methoxy-indol-3-yl methylene)-2-indolinone (FCE 28524) (50 mg).

¹H NMR (400 MHz, DMSO, δ ppm)

2.7-3.3 (m, 2H_{E+Z}); 3.5-3.8 (m, 1H_{E+Z}); 3.80-3.86 (two
5 singlets, 3H_{E+Z}); 4.4-5.2 (bs, 3H_{E+Z}); 6.45 (m, 1H_{E+Z});
6.58-6.62 (two doublets, J=6.8 Hz, J=6.8 Hz, 1H_{E+Z}); 6.85
(m, 1H_{E+Z}); 7.13 (d, J=2.2 Hz, 1H_E); 7.18 (d, J=2.2 Hz,
1H_Z); 7.23 (d, J=2.2 Hz, 1H_E); 7.40 (two doublets,
J=8.7 Hz, J=8.8 Hz, 1H_{E+Z}); 7.62 (d, J=2.6 Hz, 1H_Z); 7.76
10 (s, 1H_E); 7.94 (s, 1H_Z); 8.17 (s, 1H_E); 9.38 (s, 1H_Z);
10.00-10.05 (two singlets, 1H_{E+Z}); 11.7-12.1 (bs, 1H_{E+Z}).

FD-MS: m/z 379 (100 [M]⁺); 306 (26 [M-CH₂CHOHCH₂OH+2H]⁺)

Example 3

Preparation of FCE 28732

15 A solution of 5-aminoindole (5 g, 37.87 mmole), triethyl-
amine (10.6 ml, 76.5 mmole) and di-tert-butylpyrocarbonate
(8.35 g, 38.25 mmole) in dioxane (150 ml) was stirred at
room temperature 4 h.

The solution was concentrated under reduced pressure and
20 the residue was taken up with dichloromethane (150 ml)
and washed with water.

The organic layer was dried over sodium sulfate and
concentrated under reduced pressure, the residue was
chromatographed on silica-gel using a mixture of cyclo-
25 hexane and ethyl acetate (7:3) as eluant to give 5-

-29-

terbutoxycarbonylamino-indole (8.7 g).

A solution of 5-terbutoxycarbonylamino-indole (8.7 g, 37.5 mmole) in acetic anhydride (20 ml) was added dropwise in about 30 min in a solution of imidazole (2.65 g, 39 mmole) in acetic anhydride (20 ml) at 125°C.

After stirring 1 h the mixture was concentrated under reduced pressure and the residue was crystallized with acetonitrile, the solid was filtered and taken up with ethanol (100 ml) and water (50 ml), sodium hydroxide (5 g) was added.

After stirring 1 h at reflux the solution was diluted with water (1 l) and made neutral with 1 N hydrochloric acid, then after standing overnight at 4°C gave 5-terbutoxycarbonylamino-indole-3-carbaldehyde (5.7 g).

To a solution of 5-terbutoxycarbonylamino-indole-3-carbaldehyde (200 mg, 0.77 mmole) and 2-indolinone (100 mg, 0.75 mmole) in ethanol (15 ml) piperidine (0.06 ml, 0.6 mmole) was added at 60°C with stirring.

After stirring 4 h at 60°C the reaction mixture was diluted with dichloromethane (50 ml) and washed with water, the organic layer was dried over sodium sulfate and concentrated under reduced pressure, the residue was taken up with trifluoroacetic acid (5 ml) and stirred 1 h at 0°C.

After stirring at room temperature 1 h the mixture was diluted with dichloromethane (100 ml) and washed with 2 N sodium hydroxide and then with brine.

-30-

The organic layer was dried over sodium sulfate and concentrated under reduced pressure.

The residue was taken up with tetrahydrofuran (25 ml) and triethylamine (1.9 ml, 13.3 mmole), chlorodimethyl-
5 formiminium chloride (1.6 g, 12.6 mmole) was added portionwise at 0°C.

After the stirring was continued 1 h at room temperature, the reaction mixture was diluted with dichloromethane (150 ml) and washed with saturated sodium bicarbonate and
10 then with brine, the organic layer was dried over sodium sulfate and concentrated under reduced pressure, the residue was chromatographed on silica-gel with a mixture of ethyl acetate and methanol (1:1) as eluant to give
3-(5-dimethylaminomethyleneamino-indol-2-ylmethylene)-2-
15 indolinone (FCE 28732) (110 mg).

¹H NMR (400 MHz, DMSO, δ ppm)

2.98 (bs, 6H_{E+Z}); 6.85 (m, 2H_{E+Z}); 6.95 (m, 1H_{E+Z}); 7.04
(d, J=2.0 Hz, 1H_E); 7.10 (m, 1H_Z); 7.17 (m, 1H_E); 7.33 (d,
J=8.2 Hz, 1H_Z); 7.37 (d, J=8.5, Hz, 1H_E); 7.64 (d, J=2.0
20 Hz, 1H_Z); 7.74 (m, 2H_E); 7.79 (s, 1H_Z); 7.86 (s, 1H_E);
7.88 (d, J=7.5Hz, 1H_Z); 8.10 (s, 1H_Z); 8.13 (s, 1H_E);
9.35 (s, 1H_Z); 10.47 (bs, 1H_{E+Z}); 11.9 (bs, 1H_{E+Z}).

FD-MS: m/z 330 (100 [M]⁺)

Example 4

25 Preparation of FCE 28885

-31-

To a solution of 5-terbutoxycarbonylamino-indole-3-carbaldehyde (50 mg, 0.19 mmole) and 5-bromo-2-indolinone (40 mg, 0.19 mmole) in ethanol (5 ml) piperidine (0.02 ml, 0.2 mmole) was added with stirring at 80°C.

5 After the stirring was continued 4 h at 80°C the mixture gave a solid which

after filtration and washing with ethanol gave 3-(5-terbutoxycarbonylamino-indol-3-ylmethylene)-5-bromo-2-indolinone (70 mg).

10 The solid was taken up with trifluoroacetic acid (5 ml) and after stirring at room temperature for 1 h the mixture was diluted with ethyl acetate (100 ml) and washed with 1 N sodium hydroxide and brine.

The organic layer was concentrated under reduced
15 pressure, the residue was dissolved in N,N-dimethylformamide (15 ml) and triethylamine (0.03 ml, 0.2 mmole), bis-terbutoxycarbonylthiourea (60 mg, 0.2 mmole), HgCl₂ (80 mg, 0.2 mmole) were added with stirring.

After stirring 1 h at room temperature the mixture was
20 filtered on a pad of celite and washed with ethyl acetate.

The solution was washed with water several times and the organic layer was dried on sodium sulfate and concentrated under reduced pressure.

25 The residue was chromatographed on silica-gel with a mixture of ethyl acetate and cyclohexane (2:1) as eluant to give N-[3-(5-bromo-2-indolinone-3-ylidenemethyl)-indol-N',N''diterbutoxycarbonyl-guanidine (30 mg, 0.05

-32-

mmole).

The solid was taken up with trifluoroacetic acid (5 ml) with stirring at room temperature.

The mixture was diluted with ethyl acetate (50 ml) and
5 washed with 1N sodium hydroxide and then with brine.

The organic layer was dried on sodium sulfate and concentrated under reduced pressure, the residue was chromatographed on Lo-Bar RP-18 column with water as eluant to give N-[3-(5-bromo-2-indolinone-3-ylidene-
10 methyl)-indol-5-yl]guanidine (FCE 28885) (8 mg) after freeze-drying.

¹H NMR (400 MHz, DMSO, δ ppm)

6.79 (d, J=8.4Hz, 1H_Z); 6.85 (d, J=8.4Hz, 1H_E); 7.10 (m, 1H_{E+Z}); 7.27 (dd, J=1.8Hz, J=8.4Hz, 1H_Z); 7.37 (dd, J=1.8
15 Hz, J=8.4 Hz, 1H_E); 7.58 (m, 2H_{E+Z}); 7.83 (d, J=1.8 Hz, 1H_E); 7.90 (s, 1H_E); 8.20 (d, J=1.8 Hz, 1H_Z); 8.24 (d, J=1.8 Hz, 1H_Z); 8.27 (s, 1H_Z); 8.34 (s, 1H_E); 9.51 (s, 1H_Z); 10.64 (two singlets, 1H_{E+Z}); 12.2 (bs, 1H_{E+Z}).

FAB-MS: m/z 434 (27 [M+K]⁺); 396 (100 [M+H]⁺)

20

Example 5

Preparation of FCE 28934

To a solution of 6-nitroindole (1.62 g, 10 mmole) in tertbutanol (100 ml) pyridine hydrobromide perbromide (9.6
25 g, 30 mmole) was added portionwise in 30 min with stirring.

-33-

After the stirring was continued 1 h at room temperature the solvent was removed under reduced pressure and the residue taken up with ethyl acetate (250 ml) and washed with water. The organic layer was dried over sodium sulfate and concentrated under reduced pressure.

The residue was dissolved in acetic acid (50 ml) and zinc dust (4.3 g, 65 mmole) was added with stirring at 0°C. After 1 h the mixture was filtered on a pad of celite and washed with ethyl acetate (250 ml).

The organic layer was washed with 5% sodium bicarbonate and then with brine, the solvent was removed under reduced pressure.

The residue was dissolved in dioxane (50 ml), triethylamine (0.8 ml, 5.6 mmole) and di-tert-butylpyrocarbonate (1.2 g, 5.5 mmole) were added with stirring. After stirring 2 h at room temperature the mixture was diluted with ethyl acetate (100 ml) and washed with water.

The organic layer was dried on sodium sulfate and concentrated under reduced pressure.

The residue was chromatographed on silica-gel with a mixture of ethyl acetate and cyclohexane (1:1) as eluant to give 6-terbutoxycarbonylamino-2-indolinone (100 mg).

FD-MS: m/z 248 (100 [M]⁺)

To a solution of 6-terbutoxycarbonylamino-2-indolinone (40 mg, 0.16 mmole) and 5-methoxy-indole-3-carbaldehyde (30 mg, 0.16 mmole) in ethanol (5 ml), piperidine (0.01

-34-

ml, 0.1 mmole) was added with stirring at 80°C.

After stirring was continued 4 h at 80°C the solvent was removed under reduced pressure and the residue was chromatographed on silica-gel with a mixture of ethyl acetate and cyclohexane (1:1) as eluant to give 6-
5 terbutoxycarbonylamino-3-(5-methoxy-indol-3-ylmethylene)-2-indolinone (75 mg, 0.18 mmole).

The solid was taken up with trifluoroacetic acid (5 ml) and stirred at room temperature 15 min.

10 The reaction mixture was diluted with ethyl acetate (50 ml) and washed with 5% sodium bicarbonate, the organic layer was dried over sodium sulfate and concentrated under reduced pressure.

The residue was dissolved in tetrahydrofuran (10 ml) and
15 fluorenylmethoxycarbonyl-L-alanine (75 mg, 0.24 mmole), benzotriazol-1-yl-oxy-tripyrrolidinophosphoniumhexafluorophosphate (130 mg, 0.25 mmole) were added with stirring.

After the stirring was continued 1 h at room temperature
20 the mixture was diluted with ethyl acetate (50 ml) and washed with brine.

The organic layer was dried over sodium sulfate and concentrated under reduced pressure.

The residue was taken up with ethyl acetate (50 ml) and
25 piperidine (1 ml) was added with stirring at room temperature.

After stirring 3 h the solvent was removed under reduced pressure, at the residue was added water (5 ml), 1 N

-35-

hydrochloric acid was added dropwise until all the solid was dissolved, the solution was chromatographed on LoBar RP18 column with water as eluant to give 6-L-alanylamino-[3-(5-methoxy-indol-3-ylmethylene)-2-indolinone] (FCE 28934) (10 mg).

¹H NMR (400 MHz, DMSO, δ ppm)

1.36 (d, J=6.5 Hz, 3H_E); 1.38 (d, J=6.5 Hz, 3H_E); 3.77 (s, 3H_E); 3.80 (m, 1H_{E+Z}); 3.86 (s, 3H_Z); 6.85 (m, 1H_{E+Z}); 7.10 (m, 2H_E+1H_Z); 7.40 (m, 2H_{E+Z}); 7.68 (m, 1H_{E+Z}); 7.76 (s, 1H_E); 7.84 (d, J=8.4 Hz, 1H_Z); 8.03 (s, 1H_Z); 8.12 (d, J=2.5 Hz, 1H_E); 9.33 (d, J=2.9 Hz, 1H_Z); 10.51 (s, 1H_E); 10.52 (s, 1H_Z); 11.8 (bs, 1H_{E+Z}).

FAB-MS: m/z 377 (100 [MH]⁺); 306 (17 [MH-COCH(CH₃) NH₂+H]⁺)

15 Example 6

Preparation of FCE 28901

To a stirred solution of 5-nitroindole (4 g, 24.6 mmol) in 200 ml of t-Butanol was added, portionwise, pyridinium bromide perbromide (30 g, 93 mmol) over a period of 0.5 h. The reaction mixture was stirred at room temperature overnight, then t-Butanol was removed and the resulting residue dissolved in ethyl acetate/water (500/500 ml). The organic layer was separated and the aqueous layer was extracted with 300 ml of ethyl acetate. The organic extracts were washed with water, dried over sodium

-36-

5 sulphate anhydrous and concentrated in vacuo to give 8.5 g of a less polar compound that was recrystallized from ethyl acetate to give 7.5 g of dibromoderivative. Hydrogenation of this compound with 10 equivalents of zinc dust in 80 ml of acetic acid at room temperature for 3 h gave 5-amino oxindole in good yields (3 g, 82% yield).

EI-MS: m/z 148 (100, [M]⁺); 120 (56, [M-CO]⁺); 119 (94, [M-CO-H]⁺); 105 (22, [M-HNCO]⁺)

10 To a solution of 5-amino oxindole (2 g, 13.5 mmol) in 80 ml of water/dioxane 3:1 was added sodium hydroxide 1N until obtaining pH 10 and then di-t-Butyl pyrocarbonate (3.5 g, 16.2 mmol). The reaction was stirred for 3 h maintaining pH 10. After extraction with 3x100 ml of
15 ethyl acetate, the extracted were dried over sodium sulphate and evaporated obtaining 2.4 g of 5-t-Butoxycarbonylamino oxindole (71% yield).

¹H-NMR (400 MHz, DMSO, T=45°C)

1.49 (s, 9H); 3.87 (s, 3H); 6.72 (d, J=8.4 Hz, 1H); 6.86
20 (dd, J=2.2 Hz, J=8.8 Hz, 1H); 7.12 (dd, J=1.8 Hz, J=8.4 Hz, 1H); 7.40 (d, J=8.8 Hz, 1H); 7.54 (d, J=2.2 Hz, 1H); 7.78 (d, J=1.8 Hz, 1H); 7.92 (s, 1H); 8.87 (bs, 1H); 9.38 (s, 1H); 10.25 (s, 1H); 11.8 (bs, 1H).

FD-MS: 248 (100, [M]⁺); 191 (18, [M-C₄H₉]⁺); 147 (5, [M-
25 (CH₃)₃COCO]⁺)

-37-

To a solution of 5-t-Butoxycarbonylamino oxindole (630 mg, 2.5 mmol) and 5-methoxyindolcarboxaldehyde (450 mg, 2.6 mmol) in absolute ethanol was added piperidine (0.26 ml, 2.6 mmol). The reaction was carried out at 80°C for 3 h. Ethanol was evaporated and the residue was purified by silica gel chromatography (eluents: cyclohexane/ethyl acetate 2:3) obtaining 800 mg of product that was solubilized in 10 ml of methylene chloride and, after addition of 40 ml of trifluoroacetic acid, was stirred for 1 h at room temperature. The solvent was evaporated and the residue was crystallized with diethyl ether obtaining 750 mg of 5-amino-3-[(5'-methoxy 3'-indolyl) methylene] 2-oxindole (90% yield).

¹H-NMR (400 MHz, DMSO)

3.87 (s, 3H); 6.87 (dd, J=2.4 Hz, J=8.5 Hz, 1H); 6.90 (d, J=8.2 Hz, 1H); 7.07 (dd, J=8, 2 Hz, J=2.0 Hz, 1H); 7.42 (d, J=8.5 Hz, 1H); 7.66 (d, J=2.4 Hz, 1H); 7.81 (d, J=2.0 Hz, 1H); 8.18 (s, 1H); 9.44 (d, J=3.1 Hz, 1H); 9.65 (bs, 3H); 10.67 (s, 1H); 12.03 (d, J=3.1 Hz, 1H).

FD-MS: m/z 306 (55, [MH]⁺); 305 (100, [M]⁺)

To a solution of 5-Amino-3-[(5'-methoxy-3'-indolyl) methylene]-2-oxindole (500 mg, 1.64 mmol) and of t-Butoxycarbonyl (L)- alanine in 80 ml of tetrahydrofuran were added (950 mg, 1.87 mmol) of benzotriazole 1-yloxy-tris pyrrolidino phosphonium hexafluorophosphate and

-38-

(0.20 ml, 1.87 mmol) of N-Methylmorpholine. The reaction was carried out at room temperature for 4 h.

After evaporation of tetrahydrofuran, the residue was purified by flash chromatography (eluents: cyclohexane/
5 ethyl acetate 3:7) then, it was solubilized in methylene chloride and, after stirring for 1 h with 10 ml of trifluoroacetic acid, 600 mg of 5-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone (FCE 28901) were obtained (81% yield).

10 ¹H-NMR (400 MHz, DMSO)

1.24 (d, J=6.5 Hz, 3H); 3.46 (m, 1H); 3.87 (s, 3H); 6.76 (d, J=8.2 Hz, 1H); 6.85 (dd, J=2.4 Hz, J=8.5 Hz, 1H); 7.40 (d, J=8.5 Hz, 1H); 7.48 (dd, J=2.1 Hz, J=8.2 Hz, 1H); 7.62 (d, J=2.4 Hz, 1H); 7.89 (d, J=2.1 Hz, 1H); 8.02
15 (s, 1H); 9.41 (s, 1H); 9.8 (bs, 1H); 10.43 (s, 1H); 11.9 (bs, 1H).

FD-MS: m/z 376 (100, [M]⁺); 331 (46, [M-CH₃CH₂NH₂]⁺); 305 (24, [M-COCH(CH₃)NH₂+H]⁺)

Example 7

20 Preparation of FCE 28437

To a solution of 5-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-oxindole (600 mg, 1.42 mmol) and Boc-(L)-Glutamic acid (t-Butyl ester), (500 mg, 1.65 mmol) were added 930 mg (1.8 mmol) of benzotriazole-1-
25 yloxy-tris pirrolidino phosphonium hexafluorophosphate

-39-

and 0.20 ml (1.8 mmol) of N-Methylmorpholine. The reaction was stirred at room temperature for 3 h, then, after evaporation of tetrahydrofuran, the residue was purified by flash chromatography (eluent: ethyl acetate) obtaining 200 mg of product that was solubilized in 8 ml of methylene chloride and stirred for 1 h after addition of 8 ml of trifluoroacetic acid. The residue, solubilized in ethyl acetate, was precipitated by adding diethyl ether and purified on reversed phase (eluents: water/ methanol 1:2) obtaining 100 mg of 5-L-glutamyl-L-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone (FCE 28437) (51% yield).

¹H-NMR (400 MHz, DMSO)

1.30 (d, J=7.0 Hz, 3H_E); 1.35 (d, J=7.0 Hz, 3H_Z); 1.5-1.9 (m, 2H_{E+Z}); 2.27 (m, 2H_{E+Z}); 3.2-3.5 (m, 1H_{E+Z}); 3.81 (s, 3H_Z); 3.87 (s, 3H_Z); 4.3-4.5 (m, 1H_{E+Z}); 6.7-6.9 (m, 2H_{E+Z}); 7.21 (d, J=2.6 Hz, 1H_E); 7.25 (dd, J=1.8 Hz, J=8.4 Hz, 1H_E); 7.31 (dd, J=1.8 Hz, J=8.4 Hz, 1H); 7.40 (m, 1H_{E+Z}); 7.61 (d, J=2.6 Hz, 1H_Z); 7.85 (s, 1H_E); 7.89 (d, J=1.8 Hz, 1H_Z); 8.00 (s, 1H_Z); 8.19 (s, 1H_E); 8.3 (bs, 1H_{E+Z}); 8.5 (d, J=1.8 Hz, 1H_E); 9.41 (s, 1H_Z); 9.92 (s, 1H_Z); 10.03 (s, 1H_E); 10.35 (s, 1H_E); 10.44 (s, 1H_Z); 11.9 (bs, 1H_{E+Z}).

FAB-MS: m/z 506 (61, [M]⁺); 377 (43, [MH-Glu]⁺); 306 (100, [MH-GluAla]⁺).

-40-

Example 8

To a suspension of 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone (100 mg) in water (10 ml) the stoichiometric amount of 0,1 N HCl solution (3
5 ml) was added. The solution was freeze-dried to give 105 mg of 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone hydrochloride.

Example 9

To a suspension of 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone (25 mg) in water (10
10 ml) Amberlite Ira 900® (HCl form) was added until the solution turned clear. The resin was filtered and washed with water and the solution freeze-dried to give 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-
15 indolinone hydrochloride (20 mg).

Example 10

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.

Composition for 500 capsules:

20	3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone	10 g
	Lactose	80 g
	Corn starch	5 g
	Magnesium stearate	5 g

-41-

This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.

Example 11

Tablets, each weighing 0.150 g and containing 25 mg of
5 the active substance, can be manufactured as follows.

Composition for 10,000 tablets:

	3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl- acetyl)-2-indolinone	250 g
	Lactose	800 g
10	Corn starch	415 g
	Talc powder	30 g
	Magnesium stearate	5 g

The 3-(indol-3-yl methylene)-5-(2-piperidin-1-yl-
acetyl)-2-indolinone, the lactose and half the corn
15 starch are mixed; the mixture is then forced through a
sieve of 0.5 mm mesh size.

Corn starch (10 g) is suspended in warm water (90 ml) and
the resulting paste is used to granulate the powder. The
granulate is dried, comminuted on a sieve of 1.4 mm mesh
20 size, then the remaining quantity of starch, talc and
magnesium stearate are added, carefully mixed and
processed into tablets.

Example 12

Intravenous infusion 1-10 mg/ml.


-42-

An intravenous infusion pharmaceutical preparation can be manufactured by dissolving 50 mg of 3-(indol-3-yl methylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone in water for injection (1000 ml) and sealing glass ampoules
5 of 1-10 ml.

Prior to infusion, the obtained solution can be diluted according to the common practice, and stored and/or delivered in glass, polypropylene, polyolefin or polyethylene-lined equipment.

CLAIMS

1. Indol-3-ylmethylene-2-oxindole derivative having the following formula (I)



5 wherein

one or two of R, R₁, R₂ and R₃ are a substituent selected independently from:

- a) a -X-(CH₂)_m-NH₂, -X-(CH₂)_m-NR₄R₅, or -X-(CH₂)_m-NHR₆ group, in which X is -O-, -S- or -NH-, m is an integer of 1 to 4, one of R₄ and R₅ is hydrogen or C₁-C₆ alkyl and the other is C₁-C₆ alkyl or R₄ and R₅ taken together with the nitrogen atom to which they are linked form a C₄-C₇ saturated heteromono-cyclic ring, and R₆ is C₂-C₆ alkanoyl or the terminal carbonyl group of a peptidyl residue containing from 1 to 3 aminoacids wherein the terminal amino group is either free or in a protected form or in an alkylated form to provide a -NR₄R₅ group in which R₄ and R₅ are as defined above;
- b) a -NHC(NH)NH₂, -NHC(NH)NR₄R₅, -NHC(NH)NHR₆, -N=CH-NH₂, -N=CH-NR₄R₅ or -N=CH-NHR₆ group in which R₄, R₅ and R₆ are as defined above;

-44-

- c) a $-X-(CH_2)_m-COR_7$ group wherein X and m are as defined above, R_7 is hydroxy, amino, C_1-C_6 alkoxy or $-NR_4R_5$ in which R_4 and R_5 are as defined above, or R_7 is the terminal amino group of a peptidyl residue containing from 1 to 3 aminoacids;
- 5 d) a $-COR_8$ or COR_8 group in which R_8 is the terminal amino group of a peptidyl residue containing from 1 to 3 aminoacids and R_8 is C_1-C_4 alkoxy unsubstituted or substituted by phenyl or R_8 is a
- 10 $-(CH_2)_n-NH_2$, $-(CH_2)_n-NR_4R_5$ or $-(CH_2)_n-NHR_6$ group in which n is 1 or 2 and R_4 , R_5 and R_6 are as defined above;
- e) a $-Y-CO-Y'-R_9$ group wherein each of Y and Y' which may be the same or different is $-NH-$ or $-O-$ and R_9
- 15 is phenyl or C_1-C_6 alkyl unsubstituted or substituted by phenyl; and
- f) a $-NHR_6$ or $-NHR_{10}$ group in which R_6 is as defined above and R_{10} is C_1-C_6 alkyl substituted by 1 to 3 hydroxy groups;
- 20 and the others are independently chosen from hydrogen, halogen, amino, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, carboxy, C_1-C_6 alkoxy-carbonyl, C_2-C_6 alkanoyloxy, cyano and $-NR_4R_5$ in which R_4 and R_5 are as defined above, and the pharmaceutically acceptable
- 25 salts of salt forming compounds of formula (I).

-45-

2. A compound of formula (I), according to claim 1, wherein one of R , R_1 , R_2 and R_3 is independently a substituent selected from:

- a') $-X-(CH_2)_m-NH_2$, $-X-(CH_2)_m-NR_4R_5$ or $-X-(CH_2)_m-NHR_6$ in
5 which X is oxygen or $-NH-$, m is 1 or 2, one of R_4 and R_5 is C_1-C_4 alkyl and the other is hydrogen or C_1-C_4 alkyl or R_4 and R_5 taken together with the nitrogen atom to which they are linked form a pyrrolidine or piperidine ring, and R_6 is C_2-C_4
10 alkanoyl or the terminal carbonyl group of a peptidyl residue containing 1 or 2 aminoacids;
- b') $-NHC(NH)NH_2$ or $-N=CH-NR_4R_5$ in which one of R_4 and R_5 is C_1-C_4 alkyl and the other is hydrogen or C_1-C_4 alkyl;
- 15 c') $-X-(CH_2)_m-COR_7$ in which X is $-O-$ or $-NH-$, m is 1 or 2, R_7 is hydroxy, C_1-C_4 alkoxy, amino or R_7 is the terminal amino group of a peptidyl residue containing 1 or 2 aminoacids;
- d') a $-COR_8$ or $-COR_9$ group in which R_8 is as defined
20 above and R_9 is C_1-C_4 alkoxy unsubstituted or substituted by phenyl or R_9 is $-(CH_2)_n-NH_2$ or $-(CH_2)_n-NR_4R_5$ in which n is 1 or 2 and one of R_4 and R_5 is C_1-C_4 alkyl and the other is hydrogen or C_1-C_4 alkyl or R_4 and R_5 taken together with the
25 nitrogen atom to which they are linked form a pyrrolidine or piperidine ring; and
- e') $-NHR_6$ or $-NHR_{10}$ in which R_6 is C_2-C_4 alkanoyl or the terminal carbonyl group of a peptidyl

-46-

residue containing 1 or 2 aminoacids and R_{10} is C_1 - C_4 alkyl substituted by one or two hydroxy groups;

and the others are independently chosen from hydrogen, halogen, amino, hydroxy, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_2 - C_4 alkoxy carbonyl, C_2 - C_4 alkanoyloxy, cyano C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)-amino; and the pharmaceutically acceptable salts of salt forming compounds of formula (I).

3. A compound selected from:

- 5-aminomethylcarbonyl-3-(indol-3-yl-methylene)-2-indolinone;
- 3-(indol-3-ylmethylene)-5-(2-piperidin-1-yl-acetyl)-2-indolinone;
- 5-(2,3-dihydroxy-propylamino)-3-(5-methoxy-indol-3-ylmethylene)-2-indolinone;
- 3-(5-dimethylaminomethyleneamino-indol-2-ylmethylene)-2-indolinone;
- N-[3-(5-bromo-2-indolinone-3-ylidenemethyl)-indol-5-yl]guanidine;
- 6-L-alanylamino-[3-(5-methoxy-indol-3-ylmethylene)-2-indolinone];
- 5-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone;
- 5-L-glutamyl-L-alanylamino-3-[(5'-methoxy-3'-indolyl)methylene]-2-indolinone;

-47-

which, when appropriate, may be either a Z- or E-diastereoisomer or Z,E-mixtures of said diastereoisomers;


and the pharmaceutically acceptable salts of salt forming members of the group.

4. A process for the preparation of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salts thereof, the process comprising:

a) reacting an aldehyde of formula (II)




wherein R and R₁ are as defined in claim 1, with a compound of formula (III)



wherein R₂ and R₃ are as defined in claim 1; or



-48-

b) reacting a compound of formula (IV)




wherein

one or two of R' , R'_1 , R'_2 and R'_3 are $-OH$, $-NH_2$ or $-SH$ and the others are as R , R_1 , R_2 and R_3 as defined in claim 1, with an alkylating agent of formula (V) selected from



in which Z is a halogen atom and m , R_4 , R_5 , R_6 and R_7 are as defined in claim 1, thus obtaining a compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are as defined in claim 1 under a) or c); or


c) reacting a compound of formula (VI)



-49-

wherein

one or two of R'' , R''_1 , R''_2 and R''_3 are $-OH$ or $-NH_2$ and the others are as R , R_1 , R_2 and R_3 as defined in claim 1, with an acylating agent of formula (VII) selected from



or a reactive carbonyl derivative thereof

wherein

R_9 , R_8 , Y' and R_{10} are as defined in claim 1, thus obtaining a compound of formula (I) wherein one or two of R , R_1 , R_2 and R_3 are as defined in claim 1 under d) or e); and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof, and/or, if desired, converting a salt into a free compound, and/or, if desired, separating a mixture of isomers of a compound of formula (I) into the single isomers.

5. A pharmaceutical composition containing a suitable carrier and/or diluent and, as an active principle, a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof.

-50-

6. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, for use as a tyrosine kinase inhibitor.
7. A compound or salt, as claimed in claim 1, for use as
5 an antiproliferative agent.
8. A compound or salt, as claimed in claim 1, for use as an anti-metastatic and anti-cancer agent and in the control of angiogenesis.
9. A compound or a salt, as claimed in claim 1, for use
10 in inhibiting the development of the atheromatous plaque, in the treatment of Alzheimer's disease and as immunomodulating agent.
10. Products containing a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable
15 salt thereof, and an additional anti-tumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

INTERNATIONAL SEARCH REPORT

Int: **Patent Application No**
PCT/EP 96/01165

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D209/34 A61K31/40 C07K5/062

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 01182 (FARMITALIA CARLO ERBA S.R.L.) 21 January 1993 cited in the application see claims	1,5,6
A	WO,A,91 13055 (FARMITALIA CARLO ERBA S.R.L.) 5 September 1991 cited in the application see claims	1,5,6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 May 1996

Date of mailing of the international search report

29.05.96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/EP 96/01165

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0-A-9301182	21-01-93	AU-B- 656015	19-01-95
		AU-B- 2277792	11-02-93
		CA-A- 2091058	13-01-93
		EP-A- 0525472	03-02-93
		EP-A- 0552329	28-07-93
		HU-A- 67496	28-04-95
		JP-T- 6501494	17-02-94
		NZ-A- 243454	24-02-95
		US-A- 5409949	25-04-95
W0-A-9113055	05-09-91	AT-T- 131470	15-12-95
		AU-B- 652740	08-09-94
		AU-B- 7241291	18-09-91
		CA-A- 2053253	29-08-91
		DE-D- 69115379	25-01-96
		DE-T- 69115379	15-05-96
		EP-A- 0470221	12-02-92
		EP-A- 0662473	12-07-95
		HU-B- 210791	28-07-95
		IL-A- 97049	31-10-95
		JP-T- 4506081	22-10-92
		NZ-A- 237182	23-12-93
		US-A- 5374652	20-12-94
		US-A- 5488057	30-01-96

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.